
    
      This is an open label, single arm study which enrolled 5 subjects with SCD who previously
      participated in the GBT440-001 study (NCT02285088).

      Dosing of study drug was 2 to 6 months, depending on subject's dose assignment in the last
      administration of study drug in GBT440-001 (NCT02285088).

      The primary objective of the study was to evaluate the safety and tolerability of up to a
      total of 6 months dosing of subjects with SCD who participated in the GBT440-001 study
      (NCT02285088).
    
  